{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:28:29Z","timestamp":1740144509508,"version":"3.37.3"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T00:00:00Z","timestamp":1642550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T00:00:00Z","timestamp":1642550400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008484","name":"biomarin pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Cerliponase alfa, an enzyme replacement therapy for neuronal ceroid lipofuscinosis type 2 (CLN2), is currently available in England through a managed access agreement (MAA). It is administered every 2\u00a0weeks via an intracerebroventricular device. Here we report qualitative research with families of children with CLN2 disease and healthcare professionals (HCPs) who run the MAA, to understand how access to cerliponase alfa via the MAA at Great Ormond Street Hospital (GOSH) in London, and the overall management of CLN2 disease, was affected during the coronavirus disease 2019 (COVID-19) pandemic.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Telephone interviews were conducted with nine families, representing 11 children with  CLN2 disease, and two HCPs in November and December 2020.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Children had received cerliponase alfa treatment for a mean (SD) of 23.1\u2009\u00b1\u200924.7\u00a0months (7.1\u2009\u00b1\u20094.6\u00a0months in the MAA). Families travelled 7\u2013398\u00a0km for treatment (mean 210\u2009\u00b1\u2009111\u00a0km). Treatment with cerliponase alfa was designated \u201cessential\u201d by GOSH and continued as normal during the pandemic but with extra safety precautions, and no children missed any treatments. Families were highly motivated to continue treatment, despite considerable anxiety about the risk of coronavirus infection from travelling and staying overnight but were reassured by communications from GOSH and the safety precautions put in place. Support therapy services were widely compromised,  causing families concern about deterioration in their children\u2019s condition. Families were confused about COVID-19 testing and shielding, and were unclear whether children with CLN2 disease were vulnerable to COVID-19.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Looking forward, advice for children with  CLN2 disease should be specific and tailored, taking into account the family unit. Support therapies should be considered essential alongside cerliponase alfa treatment.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-021-02147-y","type":"journal-article","created":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T12:03:12Z","timestamp":1642593792000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of the COVID-19 pandemic on access to the cerliponase alfa managed access agreement in England for CLN2 treatment"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0443-5664","authenticated-orcid":false,"given":"Amanda","family":"Mortensen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva M.","family":"Raebel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha","family":"Wiseman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,19]]},"reference":[{"key":"2147_CR1","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1002\/humu.23860","volume":"40","author":"E Gardner","year":"2019","unstructured":"Gardner E, Bailey M, Schulz A, Aristorena M, Miller N, Mole SE. Mutation update: Review of TPP1 gene variants associated with neuronal ceroid lipofuscinosis CLN2 disease. Hum Mutat. 2019;40(11):1924\u20131938.","journal-title":"Human Mutat"},{"key":"2147_CR2","unstructured":"NICE. Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2. 2019. https:\/\/www.nice.org.uk\/guidance\/hst12."},{"key":"2147_CR3","unstructured":"BDFA. CLN2 disease, late-infantile. 2021. http:\/\/www.bdfa-uk.org.uk\/cln2-disease-late-infantile\/."},{"key":"2147_CR4","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.pediatrneurol.2017.01.034","volume":"69","author":"RE Williams","year":"2017","unstructured":"Williams RE, Adams HR, Blohm M, Cohen-Pfeffer JL, de Los RE, Denecke J, et al. Management strategies for CLN2 disease. Pediatr Neurol. 2017;69:102\u201312.","journal-title":"Pediatr Neurol"},{"key":"2147_CR5","unstructured":"European Medicines Agency. Summary of Product Characteristics. Brineura 150 mg solution for infusion. 2017 (last updated 2021). https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/brineura-epar-product-information_en.pdf"},{"key":"2147_CR6","unstructured":"European Medicines Agency. Brineura. 2017. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/brineura."},{"key":"2147_CR7","doi-asserted-by":"publisher","first-page":"213","DOI":"10.2147\/TCRM.S241048","volume":"16","author":"N Specchio","year":"2020","unstructured":"Specchio N, Pietrafusa N, Trivisano M. Changing times for CLN2 disease: the era of enzyme replacement therapy. Ther Clin Risk Manag. 2020;16:213\u201322.","journal-title":"Ther Clin Risk Manag"},{"issue":"20","key":"2147_CR8","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1056\/NEJMoa1712649","volume":"378","author":"A Schulz","year":"2018","unstructured":"Schulz A, Ajayi T, Specchio N, de Los RE, Gissen P, Ballon D, et al. Study of intraventricular cerliponase alfa for CLN2 disease. N Engl J Med. 2018;378(20):1898\u2013907.","journal-title":"N Engl J Med"},{"key":"2147_CR9","volume-title":"Brineura treatment for CLN2 disease\u2014the managed access arrangement. A guide for parents and caregivers of children with CLN2 disease","author":"RDRP","year":"2020","unstructured":"RDRP. Brineura treatment for CLN2 disease\u2014the managed access arrangement. A guide for parents and caregivers of children with CLN2 disease. Amersham: Rare Diseases Research Partnership; 2020."},{"key":"2147_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2326409818788382","volume":"6","author":"K Wyrwich","year":"2018","unstructured":"Wyrwich K, Schulz A, Nickel M, Slasor P, Ajayi T, Jacoby D, et al. An adapted clinical measurement tool for the key symptoms of CLN2 disease. J Inborn Error Metab Screen. 2018;6:1\u20137.","journal-title":"J Inborn Error Metab Screen"},{"key":"2147_CR11","unstructured":"Institute for Government Analysis. Timeline of UK coronavirus lockdowns, March 2020 to March. https:\/\/www.instituteforgovernment.org.uk\/sites\/default\/files\/timeline-lockdown-web.pdf."},{"key":"2147_CR12","unstructured":"Public Health England and Department of Health and Social Care. COVID-19: guidance on protecting people defined on medical grounds as extremely vulnerable. 2020. https:\/\/www.gov.uk\/government\/publications\/guidance-on-shielding-and-protecting-extremely-vulnerable-persons-from-covid-19."},{"key":"2147_CR13","doi-asserted-by":"publisher","first-page":"m4436","DOI":"10.1136\/bmj.m4436","volume":"371","author":"M Gill","year":"2020","unstructured":"Gill M, Gray M. Mass testing for covid-19 in the UK (editorial). BMJ. 2020;371:m4436.","journal-title":"BMJ."},{"key":"2147_CR14","unstructured":"Department of Health and Social Care. Making a support bubble with another household. 2020. https:\/\/www.gov.uk\/guidance\/making-a-support-bubble-with-another-household#who-can-make-a-support-bubble."},{"key":"2147_CR15","unstructured":"British Healthcare Business Intelligence Association. Legal and ethical guidelines for healthcare market research. 2020. https:\/\/www.bhbia.org.uk\/."},{"key":"2147_CR16","unstructured":"EURORDIS Rare Diseases Europe. 9 in 10 people living with a rare disease experiencing interruption in care because of COVID-19 (press release). 2020. https:\/\/download2.eurordis.org\/documents\/pdf\/PressRelease_COVID19surveyresults.pdf."},{"issue":"1","key":"2147_CR17","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1186\/s13023-020-01619-x","volume":"15","author":"C Lampe","year":"2020","unstructured":"Lampe C, Dionisi-Vici C, Bellettato CM, Paneghetti L, van Lingen C, Bond S, et al. The impact of COVID-19 on rare metabolic patients and healthcare providers: results from two MetabERN surveys. Orphanet J Rare Dis. 2020;15(1):341.","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"2147_CR18","doi-asserted-by":"publisher","first-page":"781","DOI":"10.3390\/children8090781","volume":"8","author":"A Tummolo","year":"2021","unstructured":"Tummolo A, Paterno G, Dicintio A, Stefanizzi P, Melpignano L, Aric\u00f2 M. COVID-19 and inherited metabolic disorders: one-year experience of a referral center. Children. 2021;8(9):781.","journal-title":"Children"},{"issue":"3","key":"2147_CR19","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ymgme.2020.09.004","volume":"131","author":"MA Elmonem","year":"2020","unstructured":"Elmonem MA, Belanger-Quintana A, Bordugo A, Boruah R, Cort\u00e8s-Saladelafont E, Endrakanti M, et al. The impact of COVID-19 pandemic on the diagnosis and management of inborn errors of metabolism: a global perspective. Mol Genet Metab. 2020;131(3):285\u20138.","journal-title":"Mol Genet Metab"},{"issue":"1","key":"2147_CR20","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1186\/s13023-021-02007-9","volume":"16","author":"E Kristal","year":"2021","unstructured":"Kristal E, Pode-Shakked B, Hazan G, Banne E, Ling G, David O, et al. The effects of the COVID-19 pandemic on patients with lysosomal storage disorders in Israel. Orphanet J Rare Dis. 2021;16(1):379.","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"2147_CR21","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1515\/jpem-2021-0067","volume":"34","author":"AB Kahraman","year":"2021","unstructured":"Kahraman AB, Yildiz Y, Ciki K, Akar HT, Erdal I, Dursun A, et al. Invisible burden of COVID-19: enzyme replacement therapy disruptions. J Pediatr Endocrinol Metab. 2021;34(5):539\u201345.","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"3","key":"2147_CR22","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ymgme.2020.04.002","volume":"130","author":"A Sechi","year":"2020","unstructured":"Sechi A, Macor D, Valent S, Da Riol RM, Zanatta M, Spinelli A, et al. Impact of COVID-19 related healthcare crisis on treatments for patients with lysosomal storage disorders, the first Italian experience. Mol Genet Metab. 2020;130(3):170\u20131.","journal-title":"Mol Genet Metab"},{"key":"2147_CR23","doi-asserted-by":"crossref","unstructured":"Andrade-Campos M, Escuder-Azuara B, de Frutos LL, Serrano-Gonzalo I, Giraldo P, Geedl, et al. Direct and indirect effects of the SARS-CoV-2 pandemic on Gaucher Disease patients in Spain: time to reconsider home-based therapies? Blood Cells Mol Dis. 2020;85:102478.","DOI":"10.1016\/j.bcmd.2020.102478"},{"key":"2147_CR24","unstructured":"Genetic Alliance UK. The rare reality of COVID-19. 2020. Genetic Alliance UK, London. https:\/\/covid-19.geneticalliance.org.uk\/wp-content\/uploads\/2020\/07\/Covid-19-Rare-Reality.pdf."},{"key":"2147_CR25","unstructured":"Action for Rare Disease Empowerment (AREDnt). Making the unseen seen: rare disease and the lessons learned from the COVID-19 pandemic. 2021. https:\/\/www.camraredisease.org\/wp-content\/uploads\/2021\/05\/ARDEnt-Report-Making-the-Unseen-Seen-May-2021-FINAL-1.pdf."},{"issue":"1","key":"2147_CR26","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13023-021-01734-3","volume":"16","author":"C Chaplin","year":"2021","unstructured":"Chaplin C. Unmasked: an insight into three patients\u2019 rare disease experiences during the COVID-19 pandemic. Orphanet J Rare Dis. 2021;16(1):88.","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"2147_CR27","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1046\/j.1365-2648.1994.20040716.x","volume":"20","author":"LT Carr","year":"1994","unstructured":"Carr LT. The strengths and weaknesses of quantitative and qualitative research: what method for nursing? J Adv Nurs. 1994;20(4):716\u201321.","journal-title":"J Adv Nurs"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-02147-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-021-02147-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-02147-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T12:04:47Z","timestamp":1642593887000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-021-02147-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,19]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2147"],"URL":"https:\/\/doi.org\/10.1186\/s13023-021-02147-y","relation":{},"ISSN":["1750-1172"],"issn-type":[{"type":"electronic","value":"1750-1172"}],"subject":[],"published":{"date-parts":[[2022,1,19]]},"assertion":[{"value":"8 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"ER and SW are employed by the RDRP, which supplies various professional services to BioMarin. AM is employed by the BDFA and was a trustee until December 2019. The BDFA has received grants from BioMarin for service development, support with public relations, raising awareness in the devolved nations of the UK, and a grant to support families with travel costs.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19"}}